Mankind Pharma Reports ₹3,570 Cr Revenue in Q1FY26, Grows 24.5% YoY with 23.8% EBITDA Margin

India’s fourth-largest pharma company posts strong domestic growth, 81.1% export surge, and 15% rise in consumer healthcare revenue led by flagship brands and new launches

 Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND), India’s fourth-largest pharmaceutical company by revenue, has reported consolidated revenue of ₹3,570 crore for the quarter ended June 30, 2025, marking a year-on-year growth of 24.5 percent. The company’s EBITDA stood at ₹850 crore, translating into a margin of 23.8 percent, an improvement of 20 basis points over the same quarter last year.
Mankind’s strong performance this quarter was led by its domestic formulation business, which contributed ₹3,101 crore in revenue, up 18.9 percent year-on-year. Its export segment also delivered a significant boost, growing by 81.1 percent to ₹469 crore, driven primarily by the consolidation of BSV and incremental gains in its base business.
The company’s consumer healthcare vertical reported ₹237 crore in revenue, representing a 15 percent increase compared to the corresponding quarter last year. This growth was supported by robust performance from its leading over-the-counter brands such as Gas-O-Fast, Manforce Condoms, HealthOk, and Preganews, which registered secondary sales growth of 36%, 18%, 15%, and 12% respectively.

Within the domestic pharmaceutical business, Mankind continued to outperform the Indian Pharmaceutical Market (IPM). Secondary sales grew by 9.2 percent versus the IPM’s 8.6 percent, with respiratory and anti-infective therapies delivering 17.8 percent and 9.1 percent growth, respectively. Chronic therapies also contributed to the outperformance, with cardiac and anti-diabetic portfolios expanding at 1.5x and 1.6x the IPM growth rate.
The company’s market share rose to 4.9 percent as of June 2025, up from 4.8 percent in March, consolidating its leadership in physician prescriptions. Mankind has maintained the number one position in India by prescription share for eight consecutive years, currently holding a 15.4 percent share, as per IQVIA June 2025 data.

Notably, the company also reported expansion in its e-commerce and modern trade (MT) channels. These accounted for 11 percent of consumer healthcare revenue in Q1FY26, compared to 9 percent in the same period last year, supported by approximately 50 percent YoY growth in digital and organised retail distribution.
On the product innovation front, Mankind Pharma continues to scale its consumer health portfolio with new launches such as Epic ThinX (premium unflavored condoms), Nimulid in pain management, and OvaNews (ovulation detection kit), positioning itself to capture growth across lifestyle and wellness categories.
Mankind’s financial data reflects both volume and portfolio expansion. Gross margins for the quarter stood at 70.5 percent, and PAT margin was 12.5 percent. Profit after tax came in at ₹445 crore, while diluted earnings per share (EPS) stood at ₹10.6.

The company’s Q1FY26 performance was also notable in the context of sequential momentum. Compared to Q4FY25, revenue rose 15.9 percent, while EBITDA was up 24 percent. This suggests operating leverage coming into play, with continued margin discipline and revenue scale.
The earnings call for Q1FY26 is scheduled on 1st August 2025 at 12:00 PM IST. Investors can access the call through the company’s designated universal access numbers or via Diamond Pass registration.
As Mankind Pharma continues to deepen its footprint across therapeutic and consumer categories, its balanced growth across prescription-led, OTC, and global markets underscores its dual focus on domestic leadership and international scale.

At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.